<DOC>
	<DOCNO>NCT01467375</DOCNO>
	<brief_summary>This trial conduct Oceania North America . The aim trial ass long term safety efficacy biphasic insulin aspart 30 subject type 2 diabetes complete BIAsp-1234 trial .</brief_summary>
	<brief_title>Long Term Safety Efficacy Biphasic Insulin Aspart 30 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Subjects must correctly include complete BIAsp1234 Persistent noncompliance study medication , visit schedule trial specific procedure precede trial Fulfilment withdrawal criterion prior include final visit BIAsp1234 . Females : breast feeding , intention become pregnant , judge use inadequate contraceptive measure ( adequate contraceptive method sterilisation , IUD ( Intra Uterine Device ) , oral contraceptive barrier method ) Known suspect allergy trial product relate product Development since entry previous trial late diabetic micro macro vascular complication , opinion Investigator indicate progressed state disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>